Author Archives: admin


Learning to be relentless – The Daily Republic

Thats something 13-year-old Floyd Korzan learned the hard way when his father, Matt, was diagnosed with acute myeloid leukemia, a highly-deadly form of blood cancer, after he fell ill on a family hiking trip in the Black Hills in 2012.

Matts fight against the disease has since taken the Mitchell family on a journey of frightening lows and celebratory highs and led Floyd to start Relentless Pledge, a non-profit organization that encourages patients to be as relentless as his father as they fight to achieve the goal of overcoming cancer.

We basically have two goals. The first one is to inspire others to overcome obstacles and dream their dreams. And the second part of the goal is to give a Relentless wristband to every cancer patient in Mitchell, our hometown, and eventually, if we get big enough, South Dakota and the United States, Floyd said in an interview with the Daily Republic.

Its a goal borne out of Floyds experience when he sat with his father at the Mayo Clinic in Rochester, Minnesota as he underwent treatments for the disease. Matt beat the leukemia once, but it later returned, a bad sign when associated with this particular kind of cancer. It went into remission again but returned again in 2017, and doctors were not hopeful.

With few options remaining, Matt agreed to a stem cell donation treatment that would use cells provided by his sister, Margaret, who happened to be a 100 percent match, injected into his system following an intense round of chemotherapy. The treatment was difficult, but after 8 million donor cells were circulated through his system, the doctors began to see good results.

Little by little, I came back, Matt said. After 30 days, they did a bone marrow biopsy that showed no evidence of leukemia whatsoever. They did another one at the end of the year, still no evidence of leukemia. They did one at the two-year mark, still no evidence of leukemia.

Visitors to relentlesspledge.org can nominate individuals to receive Relentless wristbands, which remind people to stay the course when attempting to achieve their goals. (Erik Kaufman / Republic)

Floyd recounted the scary days of his dads fight in an essay posted on his website relentlesspledge.org. He asked his father at the time how he could be as strong as he was even as he suffered from the disease and the side effects of his treatment. Matts response was that there may be times in life when the only person left who believes in you is you, and in those times, you must be relentless in order to make it through.

Floyd had found his own inspiration in his fathers fight, and he wanted to spread that inspiration to others who were suffering. Normally a private person, Matt agreed to share his story with the public and helped his son form Relentless Pledge, which encourages people to live life to the limit, to dare, to dream, and be relentless in overcoming challenges.

Visitors to the website can take the pledge, as well as nominate individuals to receive one of the symbols of the organization: a wristband bearing the word Relentless. Visitors can also order wristbands for themselves, family members, friends as well as cancer patients.

The goal is to spread the message of hope to every cancer patient in America, Floyd said. He has shipped orders of wristbands to 26 states around the country and three continents already, and the pair plan to pass out the wristbands to people in the leukemia ward at the Mayo Clinic, where Matt returns periodically for continued treatments. More wristbands will be given out at the Avera Cancer Center in Mitchell.

In total, they estimate theyve given out about 400 of them so far. And the campaign is officially less than two weeks old.

It seemed to strike a chord with people, Matt said.

As the young program grows, Floyd said the organization could expand to include more than just cancer patients in its message. There are others who are trying to accomplish goals, as well, such as public servants or community-minded individuals.

Its not all about cancer. Now were looking at giving them out to local heroes," Floyd said. "So far, weve given them to local firefighters and the librarians at the Mitchell Public Library, and were thinking about the police department."

Floyd hopes Relentless Pledge continues to grow. He is eyeing expanding the Relentless line to include t-shirts that would promote the Relentless Pledge, but for now he is concentrating on fulfilling orders for the wristbands and getting them in the hands of people who need inspiration.

I have big dreams in the future where this organization could expand to have a full line of accessories, Floyd said. Relentless gear.

Matt said he is recovering a little more each day, and hes grateful. Hes been able to throw the ball around in the yard with Floyd again, and he is working to become stronger as he continues his recovery. He said hes grateful for the love and support of Floyd as well as his wife Bam and other children Alexis, Cassidy, Hailey and Jackson. Hes thankful for doctors like Kebede Begna and Lucio Margallo, both of whom Matt described as relentless in helping him fight for his health.

And hes happy to help Floyd spread the message of hope through Relentless Pledge, he said.

I think its great. I think its a noble project, and I think its good for Floyd. Of all the ways a teenager can spend their time, this is pretty solid, Matt said.

Floyd said he plans to continue his work with the organization well into the future. He has a little over four years left before he leaves for college, and with that time he plans to do everything he can to remind those who are struggling to remain relentless.

One Relentless wristband at a time.

The next step is spreading the word, Floyd said.

More:
Learning to be relentless - The Daily Republic

Here’s Why Stemline Therapeutics Dropped Today – Motley Fool

What happened

Shares of Stemline Therapeutics (NASDAQ:STML) were down 34% at 11:42 a.m. EST after the company released disappointing preliminary fourth-quarter results.

The biotech estimates that it sold $11.8 million worth of Elzonris, a drug that treats blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer. That's lower than the $13.1 million Stemline Therapeutics sold in the third quarter -- when, as the company noted, the number of new patients on the drug increased by over 20% quarter over quarter.

Management didn't give much color on the reason for the quarter-over-quarter decline in the press release, but the company has noted in the past that BPDCN is often misdiagnosed, and it was working with doctors to increase the speed and accuracy of diagnoses. Management will likely update investors on the progress and reason for the sales slowdown during the company's presentation at the J.P. Morgan Healthcare Conference on Wednesday.

Image source: Getty Images.

The slowdown in launch trajectory is certainly disappointing, but Stemline Therapeutics has plenty of opportunities to turn things around. Elzonris is under review by EU regulators, setting up a likely approval this year.

Further down the line, there's potential to expand Elzonris into other blood cancers; the company is currently testing the drug in three different blood cancers -- chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia -- with clinical trial data in all three expected this year. There's also potential to move Elzonris into the maintenance setting for patients treating their BPDCN through a stem cell transplant; initial data in that setting is expected this quarter.

Continued here:
Here's Why Stemline Therapeutics Dropped Today - Motley Fool

Medics key to spotting signs of child abuse, Abu Dhabi conference hears – The National

The crucial need to spot the telltale signs of child abuse was high on the agenda as a global medical conference got under way in Abu Dhabi on Thursday.

Experts said doctors and nurses were well placed to uncover any early child abuse indicators, but must be clear in their diagnosis as bruising is common and can often indicate serious illnesses such as leukaemia.

The vital topic was put under the microscope during the opening sessions of the 14th Seha International Paediatric Conference at the Rosewood hotel on Al Maryah Island.

Doctors and other healthcare professionals will assess the latest developments in child healthcare during the three-day conference.

It can be the most amazing family in the world, but abuse in the home can be happening and doctors can quickly determine that with a proper physical assessment, said Dr Leslie Lehman, clinical director of paediatric stem cell transplants at Boston Childrens Hospital in the US.

A detailed history and physical exam of a child can determine the cause of bruising and rule out abuse.

Most bruises in childhood are result of minor environmental interactions.

If doctors are still unsure of the cause of bruising, a paediatric haematologist should be consulted.

Researchers also discussed breakthroughs in how to spot early signs of sepsis, paediatric hypertension, and bone and joint infections.

Delegates from some of the leading international care facilities attended the event to share their most recent findings and research.

They included experts from the Childrens Hospital in Philadelphia, the Cincinnati Childrens Hospital, Boston Childrens Hospital, National Childrens Hospital in Washington and Londons Great Ormond Street Hospital.

Abu Dhabi Health Services Company, the UAEs largest healthcare network, is hosting the 14th edition of a conference that has become one of the most prominent in the field, providing significant advantages to professionals who serve children in the UAE and the wider region.

Sehas priority is to offer children with services and treatment methods that match, if not exceed, the highest international standards, said Dr Elsadeg Mohamed Sharif, a consultant paediatrician at Al Ain Hospital.

It is dedicated to utilising the available technology and expertise worldwide to deliver on that promise.

Updated: January 16, 2020 03:05 PM

Read more:
Medics key to spotting signs of child abuse, Abu Dhabi conference hears - The National

Smart Group & A4M Concluded their First India Conference 2020 – NewsPatrolling

Smart Group & American Academy of Anti-Aging Medicine have successfully concluded their first conference featuring esteemed speakers, experts, clinicians, and researchers in the field of Integrative and Functional Medicine.

New Delhi 18 January 2020 On Saturday, January 18th, 2020, the Smart Group in partnership with A4M together held their 1st India Conference at the Hyatt Regency, New Delhi. The two-day conference featured esteemed speakers, celebrated doctors and learned professionals in the field of preventive, integrative and traditional medicine from India and across the globe.

Addressed by some of the worlds leading faculty in preventive healthcare, this groundbreaking event was attended by more than 300 doctors and featured the most cutting edge and futurists innovations in healthcare.The guest speakers at the conference were globally renowned scholars who have been leading integrative medicine globally and key leaders of the$4trillion global wellness industry which is due to swell to$30trillion.

The audience had a chance to listen to globally renowned speakers like Dr Andrew Heyman (MD, MHSA); Dr Pamela Smith (MD, MPH, MS); Dr Daniyar Jumaniyazov (MD, PhD); Dr Graham Simpson (MD); Dr Brian Delaney (PHD) and Indian health leaders like Deepak A V Chaturvedi (MD), endocrinologist from Mumbai; Alok Sharma, President, Stem Cell Society India; Dr BS Rajput Vice President , Stem Cell Society India ; functional medicine experts like celebrity nutritionist, Dr Anjali Hooda amongst others.

A series of sessions as conducted by renowned industry experts, featured new age topics including intermittent fasting, regenerative medicine, autoimmunity, biochemical detox, and sub-fertile male amongst others, all of which have taken urban India by storm and are being increasingly endorsed by celebrities from Bollywood, sports and even politics. A key feature of the conference was the scientifically curated exhibition featuring nutraceutical providers, companies in cellular regeneration & gene testing, healthcare equipments enabled by artificial intelligence. Healthcare stalwarts like Dabur and Apollo showcased their futuristic vision for healthcare in India

Keeping with the futuristic theme of the conference, Dr M (BK Modi) Founder-Chairman, Smart Group, addressed the audience via a video conference. Detailing his own experience with stem cells, he said, I am very glad that doctors in India are taking a keen interest in preventive health. Cellular therapy has personally given me a renewed zeal and has enabled me to pursue my passion despite my age. I wish more people discover the benefits of preventive health, and can lead happy & healthy lives, beyond 100.

The thought was echoed by Ms Preeti Malhotra (Chairman, Smart Bharat and President Organising committee, Smart A4M India conference, Medicine has taken an exponential leap this century. Preventive health has had a profound effect on human longevity, awareness, mental wellbeing. There are researches claiming that children born in the coming years may live for upto a 1000 years, this has a profound effect on social relations, economies and the future of a nation. I am very happy that we were a able to bring A4M into India to initiate this conversation, much needed in a country like ours.

Given the resounding success of Smart Group & A4Ms 1st India Conferences Day 1, its hoped that the Day 2 shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Read more from the original source:
Smart Group & A4M Concluded their First India Conference 2020 - NewsPatrolling

Introducing Generate Life Sciences – A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families – Yahoo Finance

With over 40+ years of leadership and expertise in reproductive, newborn stem cell, and genetic services, Generate has already helped grow and protect nearly 1 million families around the world

LOS ANGELES, Jan. 13, 2020 /PRNewswire/ --California Cryobank Life Sciences today announced the launch of its new company brand - Generate Life Sciences (Generate). The rebranding follows the joining of California Cryobank and CBR (Cord Blood Registry) in August 2018 and represents the company's mission to become a life sciences platform that helps grow and protect healthy families through reproductive, newborn stem cell, genetic testing, medical device and healthcare technology services.

Generate serves families from preconception to post-birth throughout the significant and highly personalized journey of building a family and protecting their children's health. Built upon the pillars of innovation, access, and connection, Generate has already helped grow and protect nearly 1 million families around the world.

Our legacy brands CBR, California Cryobank, and Donor Egg Bank USA are pioneering leaders in their respective fields and continue to set industry standards for innovation, scientific excellence, and customer focus. Generate is furthering the impact of this life sciences platform with the addition of advanced pediatric genetic testing, US distribution of reproductive medical devices and proprietary healthcare technology through the respective brands ReadyGen (pediatric genetic screening powered by Sema4), Kitazato USA (medical device distribution), and Donor Application (proprietary software for reproductive clinics).

"Our brands are leaders in each of their categories; as a life sciences platform, we are uniquely positioned to give clients access to the full range of expertise and services needed to create and support healthy families," said Richard Jennings, Chief Executive Officer. "Generate helps its clients realize their dreams of having a baby and provides access to scientific innovations in stem cells and genetic services that improve the lives of families around the world."

With the substantial growth in single parenting by choice and LGBTQ+ family building, as well as a trend towards having children later in life, Generate's reproductive health services have never been in higher demand. Similarly, advances in stem cell therapies and research into regenerative medicine have emphasized the importance and increased the awareness and interest in storing newborn stem cells with CBR.

"Generate Life Sciences is positioned to play an increasingly important role in protecting families as regenerative medicine and new genetic testing platforms open the door to the future of personalized medical treatments," said Jaime Shamonki, MD, Chief Medical Officer. "Uniting key elements of the family-building experience under Generate will give our clients peace of mind, convenient access, and exceptional support throughout this significant time in their lives. This organization has collectively helped create nearly 100,000 families and provides access to invaluable long-term health benefits to almost a million more. For us, Generate represents more than just good business; it is advancing scientific innovations that help the future of humanity."

"The journey to parenthood has evolved over the years, but the end goal is the same people want to have children and they want to keep them safe and healthy. In the modern age, we have advanced the science and technology available to help individuals grow their families and be more proactive in planning for their future health," said Michael J. Levy, MD, IVF Director and Co-Founder, Shady Grove Fertility. "That is where Generate Life Sciences becomes a trusted partner for clients from pre-conception through post-birth. From donor egg and donor sperm to newborn stem cell services and genetic testing, Generate is there every step of the way. And the possibilities are endless."

"Generate Life Sciences made our dream of becoming parents a reality. From helping us choose our amazing California Cryobank sperm donor for our twin girls, to rushing a CBR cord blood collection kit for our son when my wife went into early labor, they have always gone above and beyond to help. We look to Generate as a trustworthy partner we can rely on for these very personal and private moments in our lives," said Sharon Kochlany & Vanessa Colimorio, customers of Generate.

Story continues

Generate Life Sciences BrandsGenerate Life Sciences is a company of established, trustworthy brands founded and grown over 40 years by experts in reproductive medicine, newborn stem cell services, and genetics. Those brands include:

Newborn Stem Cell Services CBR (Cord Blood Registry): CBR has stored newborn stem cells (stem cells collected from cord blood and cord tissue) for almost 30 years.

Reproductive ServicesCalifornia Cryobank Donor Sperm Bank:California Cryobank is a pioneer and industry leader in donor sperm banking, offering the most rigorously screened donors, largest selection, and scientific expertise for more than 40 years.

Donor Egg Bank USA:Donor Egg Bank is a true leader in its category, maintaining the highest clinical pregnancy rate in the industry, while growing the largest frozen donor egg program in the United States.

NW Cryobank:For over 30 years, NW Cryobank has been helping couples, single women, and the LGBTQ+ community create happy, healthy families.

Genetic Services ReadyGen:Powered by Sema4, ReadyGen is an innovative and advanced pediatric screening test that empowers parents to further protect their children by delivering clinically actionable and personalized health insights.

Medical Devices and Healthcare TechnologyKitazato USA:Kitazato USA by California Cryobank is the exclusive distributor of Kitazato products in the US, offering devices for human assisted reproductive medicine from the innovator of the Cryotop Method vitrification technique.

Donor Application: Proprietary software providingdonor screening and recipient matching services on a HIPAA compliant platform.

About Generate Life SciencesGenerate Life Sciences (Generate)is a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services. We serve families from preconception to post-birth. Our brands - CBR (Cord Blood Registry), California Cryobank Donor Sperm Bank, Donor Egg Bank USA, NW Cryobank, ReadyGen, Kitazato USA, and Donor Application are pioneering leaders, helping to grow and protect nearly 1 million families. Headquartered in Los Angeles, Generate operates facilities in Tucson, New York, Boston, Palo Alto, and Rockville, MD. Generate is a portfolio company of GI Partners, a private investment firm based in San Francisco.

Media ContactsMonica Rohledermedia@generatelifesciences.com847-606-1973

Between Life and Science is Opportunity

View original content to download multimedia:http://www.prnewswire.com/news-releases/introducing-generate-life-sciences--a-first-of-its-kind-company-focused-on-helping-grow-and-protect-healthy-families-300985444.html

SOURCE Generate Life Sciences

Read more here:
Introducing Generate Life Sciences - A First-Of-Its-Kind Company Focused On Helping Grow And Protect Healthy Families - Yahoo Finance

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer – Yahoo Finance

CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option agreement to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture allogeneic engineered natural killer (NK) cells and non-alpha beta T cell medicines for the treatment of cancer.

This collaboration brings together Editas Medicines leading genome editing technology and Sandhills BINATE product process, a novel universal donor technology to extract, isolate, and expand NK cells and non-alpha beta T cells, to develop novel medicines for the treatment of solid tumor cancers.

We are excited to work with Sandhill, combining CRISPR-based genome editing with BINATE cells to accelerate the development of numerous, transformative medicines for people with cancer and improve patient outcomes, said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. We continue to increase our commitment to oncology, and we believe our portfolio of multiple immune system cell types, including T cells, NK cells, and induced pluripotent stem cells (iPSCs), will be effective in making the next generation of allogeneic medicines to fight many common cancers.

The team at Editas Medicine has one of the most innovative technology platforms, and we look forward to combining our technologies to create new medicines for the treatment of cancer. Together, we are dedicated to transforming cellular immuno-oncology and developing new therapies, said Annemarie Moseley, M.D., Ph.D., Chief Executive Officer, Sandhill Therapeutics, Inc.

Under the terms of the agreement, Editas Medicine obtains an exclusive license to Sandhills technology to research, develop and commercialize immuno-oncology engineered cell medicines for solid tumors originating within a given area of the body and an option to expand such license to two additional areas. In return, Sandhill will receive an upfront payment, development and sales-based milestone payments, and royalties on sales of resulting Editas products.

RBC Capital Markets acted as exclusive financial advisor to Sandhill for the transaction.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

About Sandhill Therapeutics, Inc.Sandhill Therapeutics is a privately held, development stage cellular immunotherapy company dedicated to improving the lives of children and adults with cancer. Sandhills BINATE leverages dual innate cell synergy, resulting in a highly activated, readily available, universal off-the-shelf treatment for both solid tumors and blood cancers. Sandhills activated innate cell immunotherapy is generated by a cost-effective, feeder-free campaign manufacturing process. For more information, visitwww.sandhilltx.com.

Editas Medicine Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Editas Medicines product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicines foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in Editas Medicines most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release representEditas Medicinesviews only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law,Editas Medicineexplicitly disclaims any obligation to update any forward-looking statements.

Story continues

See more here:
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer - Yahoo Finance

Stem Cell Research: Uses, Types & Examples

Stem cells are undifferentiated, or blank, cells. This means theyre capable of developing into cells that serve numerous functions in different parts of the body. Most cells in the body are differentiated cells. These cells can only serve a specific purpose in a particular organ. For example, red blood cells are specifically designed to carry oxygen through the blood.

All humans start out as only one cell. This cell is called a zygote, or a fertilized egg. The zygote divides into two cells, then four cells, and so on. Eventually, the cells begin to differentiate, taking on a certain function in a part of the body. This process is called differentiation.

Stem cells are cells that havent differentiated yet. They have the ability to divide and make an indefinite number of copies of themselves. Other cells in the body can only replicate a limited number of times before they begin to break down. When a stem cell divides, it can either remain a stem cell or turn into a differentiated cell, such as a muscle cell or a red blood cell.

Since stem cells have the ability to turn into various other types of cells, scientists believe that they can be useful for treating and understanding diseases. According to the Mayo Clinic, stem cells can be used to:

There are several types of stem cells that can be used for different purposes.

Embryonic stem cells come from human embryos that are three to five days old. They are harvested during a process called in-vitro fertilization. This involves fertilizing an embryo in a laboratory instead of inside the female body. Embryonic stem cells are known as pluripotent stem cells. These cells can give rise to virtually any other type of cell in the body.

Adult stem cells have a misleading name, because they are also found in infants and children. These stem cells come from developed organs and tissues in the body. Theyre used by the body to repair and replace damaged tissue in the same area in which they are found.

For example, hematopoietic stem cells are a type of adult stem cell found in bone marrow. They make new red blood cells, white blood cells, and other types of blood cells. Doctors have been performing stem cell transplants, also known as bone marrow transplants, for decades using hematopoietic stem cells in order to treat certain types of cancer.

Adult stem cells cant differentiate into as many other types of cells as embryonic stem cells can.

Scientists have recently discovered how to turn adult stem cells into pluripotent stem cells. These new types of cells are called induced pluripotent stem cells (iPSCs). They can differentiate into all types of specialized cells in the body. This means they can potentially produce new cells for any organ or tissue. To create iPSCs, scientists genetically reprogram the adult stem cells so they behave like embryonic stem cells.

The breakthrough has created a way to de-differentiate the stem cells. This may make them more useful in understanding how diseases develop. Scientists are hoping that the cells can be made from someones own skin to treat a disease. This will help prevent the immune system from rejecting an organ transplant. Research is underway to find ways to produce iPSCs safely.

Cord blood stem cells are harvested from the umbilical cord after childbirth. They can be frozen in cell banks for use in the future. These cells have been successfully used to treat children with blood cancers, such as leukemia, and certain genetic blood disorders.

Stem cells have also been found in amniotic fluid. This is the fluid that surrounds a developing baby inside the mothers womb. However, more research is needed to help understand the potential uses of amniotic fluid stem cells.

Adult stem cells dont present any ethical problems. However, in recent years, there has been controversy surrounding the way human embryonic stem cells are obtained. During the process of harvesting embryotic stem cells, the embryo is destroyed. This raises ethical concerns for people who believe that the destruction of a fertilized embryo is morally wrong.

Opponents believe that an embryo is a living human being. They dont think the fertilized eggs should be used for research. They argue that the embryo should have the same rights as every other human and that these rights should be protected.

Supporters of stem cell research, on the other hand, believe that the embryos are not yet humans. They note that researchers receive consent from the donor couple whose eggs and sperm were used to create the embryo. Supporters also argue that the fertilized eggs created during in-vitro fertilization would be discarded anyway, so they might be put to better use for scientific research.

With the breakthrough discovery of iPSCs, there may be less of a need for human embryos in research. This may help ease the concerns of those who are against using embryos for medical research. However, if iPSCs have the potential to develop into a human embryo, researchers could theoretically create a clone of the donor. This presents another ethical issue to take into consideration. Many countries already have legislation in place that effectively bans human cloning.

In the United States, federal policy regarding stem cell research has evolved over time as different presidents have taken office. Its important to note that no federal regulation has ever explicitly banned stem cell research in the United States. Rather, regulations have placed restrictions on public funding and use. However, certain states have placed bans on the creation or destruction of human embryos for medical research.

In August 2001, former President George W. Bush approved a law that would provide federal funding for limited research on embryonic stem cells. However, such research had to fit the following criteria:

In March 2009, President Barack Obama revoked former President Bushs statement and released Executive Order 13505. The order removed the restrictions on federal funding for stem cell research. This allowed the National Institutes of Health (NIH) to begin funding research that uses embryonic stem cells. The NIH then published guidelines to establish the policy under which it would fund research. The guidelines were written to help make sure that all NIH-funded research on human stem cells is morally responsible and scientifically relevant.

Stem cell research is ongoing at universities, research institutions, and hospitals around the world. Researchers are currently focusing on finding ways to control how stem cells turn into other types of cells.

A primary goal of research on embryonic stem cells is to learn how undifferentiated stem cells turn into differentiated stem cells that form specific tissues and organs. Researchers are also interested in figuring out how to control this process of differentiation.

Over the years, scientists have developed methods to manipulate the stem cell process to create a particular cell type. This process is called directed differentiation. A recent studyalso discovered the first steps in how stem cells transform into brain cells and other types of cells. More research on this topic is ongoing.

If researchers can find a reliable way to direct the differentiation of embryonic stem cells, they may be able to use the cells to treat certain diseases. For example, by directing the embryonic stem cells to turn into insulin-producing cells, they may be able to transplant the cells into people with type 1 diabetes.

Other medical conditions that may potentially be treated with embryonic stem cells include:

Californias Stem Cell Agency provides a detailed list of the disease programs and clinical trials currently underway in stem cell research. Examples of such projects include:

Researchers are also using differentiated stem cells to test the safety and effectiveness of new medications. Testing drugs on human stem cells eliminates the need to test them on animals.

Stem cell research has the potential to have a significant impact on human health. However, there is some controversy around the development, usage, and destruction of human embryos. Scientists may be able to ease these concerns by using a new method that can turn adult stem cells into pluripotent stem cells, which can change into any cell type. This would eliminate the need for embryonic stem cells in research. Such breakthroughs show that much progress has been made in stem cell research. Despite these advancements, theres still a lot more to be done before scientists can create successful treatments through stem cell therapy.

Read the original post:
Stem Cell Research: Uses, Types & Examples

Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News – Dagoretti News

About global Stem Cell Assay market

The latest global Stem Cell Assay market study is an in-depth and professional assessment of the current situation of the global Stem Cell Assay industry, including market size, revenue, pricing, trends, and future prospects. According to the report, the global Stem Cell Assay market pegged a value of ~US$ xx Mn/Bn in 2018 and is expected to progress at a CAGR of xx% during the foreseeable timeframe 2019-2029.

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=19364

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report answers some of the important questions, including:

The report provides the following data:

Buy reports at discount prices!!!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report presents accurate and up-to-date insights regarding the Stem Cell Assay market from trusted suppliers, service providers, and value chain partners via extensive primary and secondary research. The information regarding each market vendor includes company background, main market insight, SWOT analysis, sales, revenue, pricing and gross margin, and market share.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Mr. Rohit BhiseyTransparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

Read more:
Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News - Dagoretti News

2D Cell Culture Market to Witness Growth Acceleration During 2020 to 2026 Dagoretti News – Dagoretti News

Global Marketers.biz offers newly published a research report titled, Global 2D Cell Culture Market Research Report 2020. Primary and secondary research methodologies have been used to formulate this report. The analysis has been derived using historic and forecast. The industry is expected to thrive in terms of volume and value during the forecast years. This report offers an understanding of various drivers, threats, opportunities, and restraints in the market. Analysts have used SWOT and Porters five forces analysis to determine the effect these factors will have on the market growth during the forecast period. The 2D Cell Culture industry report includes in-depth examination of geographical regions, revenue forecasts, segmentation, and market share.

For More Details, Get a Sample Copy of This Report (Including Full TOC, Table & Figures) @: https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #request_sample

Key players profiled in the report on the global 2D Cell Culture Market are:

Emd MilliporeCedarlane LaboratoriesATCCAbcamBiolaminaThermo Fisher ScientificBecton DickinsonBio-Techne3PbioIbdiCell Guidance SystemsMerck MilliporeCorningBiomedtech LaboratoriesGE Life ScienceCell Culture CompanyCellsystemsGreiner Bio-One International AgSigmaaldrichSigma-Aldrich

Global 2D Cell Culture Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global 2D Cell Culture Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the global 2D Cell Culture market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global 2D Cell Culture Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The global 2D Cell Culture market is segmented

on the basis of product type, applications, and its end users.

Global 2D Cell Culture Market by Type:

SkinLungBrainKidneyLiverBreastOthers

Global 2D Cell Culture Market by Application:

PharmaceuticalStem Cell ResearchComparative Genome SequencingBioproductionFood ApplicationBioenergyEnvironment Testing and ToxicologyAgriculture

Global 2D Cell Culture Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, Europe, Asia Pacific, and the Middle East and Africa.

2D Cell Culture Market Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #inquiry_before_buying

In this study, the years considered to estimate the market size of Network Traffic Analysis Software are as follows:

Highlights of TOC:

Executive Summary: The report starts with an easy-to-read, easy-to-understand summary of the entire market research study to help readers to gain quick understanding of the global 2D Cell Culture market.

Company Profiles: This section provides key details about the business and market growth of leading players of the global 2D Cell Culture market.

Market Dynamics: The report offers comprehensive analysis of key growth drivers, restraints, trends, and opportunities of the global 2D Cell Culture market.

Market Forecasts: Here, the report offers accurate market size forecasts for the global 2D Cell Culture industry, its segments and sub-segments, and all regions considered for the study.

Recommendations: Market recommendations provided in the report are very specific and research-backed. They have been created to help players move in the right direction during their journey to achieve success in the global 2D Cell Culture market.

Explore Full 2D Cell Culture Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #table_of_contents

We Also Offer Customization on report as per clients specific Requirement:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad ([emailprotected]).

For more relevant information visit @ https://www.globalmarketers.biz

Read the original post:
2D Cell Culture Market to Witness Growth Acceleration During 2020 to 2026 Dagoretti News - Dagoretti News

The Clinical Trial that MS Patients Have Been Waiting For – Multiple Sclerosis News Today

People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and its enrolling people with MSat several centers in the United States and one in the United Kingdom.

The U.S. has been behind the curve when it comes to approving stem cell treatments for people with MS. Autologous hematopoietic stem cell transplantation (aHSCT) has been available in Mexico and Russia for several years, but isnt widely available in the U.S.

In the procedure, doctors collect a patients blood-forming stem cells, give the patient high-dose chemotherapy to deplete the immune system, and then return the patients own stem cells to rebuild the immune system. The system, hopefully, returns free of cells believed to be involved with MS.

Three years ago, following a promising aHSCT study, Dr. Anthony Fauci was optimistic but cautious. Fauci is the director of the National Institute of Allergy and Infectious Diseases. He said, These extended findings suggest that one-time treatment with HDIT/HCT may be substantially more effective than long-term treatment with the best available medications for people with a certain type of MS. But Fauci emphasized that a larger trial was still necessary. It appears that trial has finally arrived.

The Phase 3 trial, called BEAT-MS (NCT04047628), will put aHSCT head-to-head against the top-line disease-modifying therapies (DMTs) available in the U.S. to treat MS.

It will enroll 156 adults, ages 18 to 55, with a diagnosis of relapsing-remitting MS (RRMS) at 21 sites 20 in the U.S. and one in the U.K. Participants will be randomly assigned to receive either aHSCT or one of the high-efficacy MS treatments currently in use: Ocrevus (ocrelizumab), Lemtrada/Campath (alemtuzumab), Tysabri (natalizumab), or Rituxan (rituximab). The participants, who wont know which treatment theyre receiving, will be followed for six years.

In a news release, investigators said they want to compare how much time elapses between the start of the treatment and an MS relapse. Theyll also compare the newly developing immune systems of the participants who receive aHSCT with the immune systems of those who receive a DMT.

Finally, theyll compare the effects of the two treatment types on other measures of disease activity and severity, their cost-effectiveness in terms of healthcare costs and productivity, and participants quality of life. We hope that BEAT-MS will clarify the best way to treat people with relapsing MS, said Dr. Jeffrey Cohen, the trials leader.

I hope so, too. A study such as this is long overdue. But I think I echo the feelings of many people with MS when I express dismay that were probably still at least six years away from approval of aHSCT in the U.S.

As I wrote three years ago, [S]cientists have been studying stem cell treatments for years and it sure seems as if were still crawling when we should be cruising. Also, why limit this study to people with RRMS? Why not include those with primary and secondary progressive MS? Am I wrong to think that they would benefit from aHSCT as much, if not more, as those with relapsing MS?

What do you think?

Starting this month, Multiple Sclerosis News Today columnist Jennifer Powell and I have begun recording MS news and feature stories in audio format. Jennifers audio reports are available on SoundCloud every Monday, and mine are available every Thursday. Click here to give us a listen.

Youre invited to visit my personal blog at http://www.themswire.com.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

See the article here:
The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today